PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.
Also called NCT01581073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 476 participants
- Registry
-
NCT01581073
-
- Other papers using this trial's data
- Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
- Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01581073. Randomized; no masking; primary purpose treatment. Start 2012-02-16 (actual); primary completion 2017-12-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
- Acronym
- PREDICT
- Condition
- Chronic Kidney Disease
- Condition
- Diabetes
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Collaborator
- Showa University School of Medicine
Record details
- Record id
cardio:ct-nct01581073- Content hash
2d2ca93bc4b0d24e949c7b9ab8af85e2976e36e30ea1dff3c4ada06a7a7eb04e